Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PollenVax in Mugwort Pollen-Induced Allergic Rhinitis
NCT07563439Phase 2Recruiting
- Sponsor
- Kazakh National Agrarian Research University
- Start
- May 2026
- Primary completion
- Sep 2026
- Modality
- Allergy Immunotherapy
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of artemisia pollen allergen extract in allergic rhinitis (AR) (3 arms), sponsored by Kazakh National Agrarian Research University. Primary endpoints: Combined Symptom and Medication Score at 22 weeks and Incidence and Severity of Adverse Events at 26 weeks. Started May 2026; status: recruiting.
02
Drugs
artemisia pollen allergen extract
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT07563439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07563439.